Statins and sepsis: panacea or Pandora's box? - Authors' reply

Marius Terblanche; Yaniv Almog; Robert S. Rosenson; Daniel G. Hackam

doi:10.1016/S1473-3099(07)70004-X

Statins and sepsis: panacea or Pandora's box? - Authors' reply

Marius Terblanche, Yaniv Almog, Robert S. Rosenson, Daniel G. Hackam

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	80-81
Number of pages	2
Journal	The Lancet Infectious Diseases
Volume	7
Issue number	2
DOIs	https://doi.org/10.1016/S1473-3099(07)70004-X
State	Published - Feb 2007
Externally published	Yes

Access to Document

10.1016/S1473-3099(07)70004-X

Cite this

@article{e8baafcdc5594f9cac2b8e8952dbdb91,

title = "Statins and sepsis: panacea or Pandora's box? - Authors' reply",

author = "Marius Terblanche and Yaniv Almog and Rosenson, {Robert S.} and Hackam, {Daniel G.}",

note = "Funding Information: RSR has received research grants from AstraZeneca, Merck, and Pfizer, and speaker's fees from AstraZeneca and Merck. MT, YA, and DGH have no conflicts of interest to declare.",

year = "2007",

month = feb,

doi = "10.1016/S1473-3099(07)70004-X",

language = "English",

volume = "7",

pages = "80--81",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Statins and sepsis

T2 - panacea or Pandora's box? - Authors' reply

AU - Terblanche, Marius

AU - Almog, Yaniv

AU - Rosenson, Robert S.

AU - Hackam, Daniel G.

N1 - Funding Information: RSR has received research grants from AstraZeneca, Merck, and Pfizer, and speaker's fees from AstraZeneca and Merck. MT, YA, and DGH have no conflicts of interest to declare.

PY - 2007/2

Y1 - 2007/2

UR - http://www.scopus.com/inward/record.url?scp=33846454336&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(07)70004-X

DO - 10.1016/S1473-3099(07)70004-X

M3 - Letter

C2 - 17251076

AN - SCOPUS:33846454336

SN - 1473-3099

VL - 7

SP - 80

EP - 81

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 2

ER -